Benzinga | Jan 12, 2021 07:09AM EST

SVB Leerink Maintains Outperform on Blueprint Medicines, Raises Price Target to $127

SVB Leerink analyst Andrew Berens maintains Blueprint Medicines (NASDAQ:BPMC) with a Outperform and raises the price target from $121 to $127.